Non-compliance with methodological requirements for QoL evidence impairs chances for positive benefit evaluation.

prostate cancer) (C60-63), 10.7% had malignant neoplasms of digestive organs (C15-26) and 8,4% showed malignant neoplasms of ill-defined, secondary and unspecified sites (C76-80). The outpatient diagnosis rate for CLL was 94.9%, inpatient rate 0.6% and in-and outpatient rate 4.6%. Overall, 266 of 1,405 pts (18.9%) (175 men [65.8%], 91 women [34.2%]) received chemotherapy in 2012 (ATC Code L01* 74.1%, PZN 9999092 23.0%, OPS 854* 2.9%). Most patients received outpatient treatment (94.0%), with 5.3%of patients received both out-and inpatient treatment and 0.7% inpatient treatment. The most commonly used treatments were rituximab (26.7%), bendamustine (20.2%), chlorambucil (11.1%), cyclophosphamide (7.7%), fludarabine (6.2%) and other treatments (28.1%). ConClusions: The majority of patients being diagnosed with CLL did not require treatment within a time period of a year. Approximately 1/3 of patients had a second malignancy, predominantly skin cancer. Treatment was primarily composed of chemotherapy or chemoimmunotherapy.objeCtives: To estimate the annual number of patients in France with Acute Myeloid Leukemia (AML) and MyeloDysplasic Syndrom (MDS) and treated with intensive chemotherapy susceptible to induce neutropenia. Methods: French hospital databases named PMSI record medical information about all the hospitalizations performed annually in France. From 2006 to 2012, databases allow linking the stays over time of a given patient with an anonymous number. In this study, PMSI databases were used to identify patient, aged more than 15, with diagnosis of AML or MDS and who were alive during the year 2012. Then, patients who underwent hospital stays for chemotherapy during more than 5 days were identified and considered as neutropenic according to experts opinions. Results: Since 2006, 51,386 patients with at least one diagnosis of AML or MDS and aged more than 15 were identified, from which only, 16,006 had at least one hospital stay in 2012 and 3,468 were hospitalized more than 5 days for chemotherapy. Among those patients, 55.2% were male, mean age was 60.4 years, 30% died during a hospital stay and 19% (664) were bone marrow grafted during the year 2012. These patients had 1.8 stays for chemotherapy per year with average chemotherapy duration of 27 days. Two third of these patients (34%) were diagnosed in 2012 and 23% in 2011. ConClusions: Among the 16,006 patients diagnosed AML or SMD and hospitalized in France in 2012, 3, 468 (21%) received intensive chemotherapy inducing neutropenia, putting them at high risk of invasive fungal infection.

s227 regression model was used to account for the heterogeneous nature of the distribution of the estimated subjective life expectancy of the study participants and therefore identify components of such distribution. Results: Mean subjective life expectancy in older people varied according to four components. The average subjective life expectancy among elderly people was 79.51, 78.89, 80.02 and 77.79 years in the first (24.73% of the sample), second (20.97%), third (33.33%) and fourth (20.97%) component of the elders' overall subjective life expectancy respectively. The effect of sociodemographic characteristics, comorbidities, and lifestyle on subjective life expectancy varied across components. As an example, a U-shape relationship between household per capita income and subjective life expectancy has been established for individuals belonging to the third component while an inverse U-shape relationship was found for individuals belonging the fourth component. ConClusions: We extended the concept of subjective life expectancy by accounting for the heterogeneity in the distribution of the estimated subjective life expectancy. This approach may provide more insights into elderly people's perceptions regarding aging, which could be used to forecast the demand for health services and long-term care needs.

No abstract